The Swedish biotech has held positive talks with US regulators about the Phase III design for its pancreatic cancer candidate, mitazalimab. Now it needs to pin down a partner.
It looked like the writing was on the wall for Alligator Biosciences after the Swedish company slashed its workforce and ended its early-stage R&D activities at the end of last year but 2025 has started well for the firm and its pancreatic cancer candidate, mitazalimab.
Cash-strapped Alligator said in December that it would “adjust the size of its organization and scope of operations” to reflect...
Create an account to read this article
Already a subscriber?
Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.
Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
